3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
6
Gastrointestinal
6
Endocrine
6
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
697
Urinary Bladder Neoplasms
256
Carcinoma, Renal Cell
190
Kidney Neoplasms
94
Neoplasms
72
Carcinoma, Transitional Cell
69
Breast Neoplasms
66
Lung Neoplasms
38
Ovarian Neoplasms
37
Melanoma
37
Colorectal Neoplasms
37
Stomach Neoplasms
36
Non-Muscle Invasive Bladder Neoplasms
35
Neoplasm Metastasis
33
Pancreatic Neoplasms
31
Carcinoma, Non-Small-Cell Lung
29
Recurrence
26
Colonic Neoplasms
25
Uterine Cervical Neoplasms
20
Urologic Neoplasms
20
Testicular Neoplasms
20
Esophageal Neoplasms
20
Liver Neoplasms
18
Head and Neck Neoplasms
18
Disease
18
Wilms Tumor
17
Carcinoma, Hepatocellular
17
Endometrial Neoplasms
16
Sarcoma
15
Prostatic Hyperplasia
15
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastro-enteropancreatic neuroendocrine tumor
×
Genitourinary
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled